Asthma Severity in Four Countries of Latin America

Overview

Journal BMC Pulm Med

Publisher Biomed Central

Specialty Pulmonary Medicine

Date 2019 Jul 11

PMID 31288777

Citations 7

Authors

Hugo Neffen

Felipe Moraes

Karynna Viana

Valentina Di Boscio

Gur Levy

Claudia Vieira

Gabriela Abreu

Claudia Soares

Affiliations

Soon will be listed here.

Abstract

Background: In Latin America, there is scarce information about severe asthma (SA) according to the ERS/ATS 2014 criteria. This study aimed to compare the demographic, socio, clinical characteristics, treatment, and use of healthcare resources between SA and non-severe asthma (NSA) patients in Argentina, Colombia, Chile and Mexico.

Methods: A cross-sectional study was conducted including 594 asthma patients from outpatient specialized sites. A descriptive analysis was performed comparing SA patients and NSA. Chi-square and Mann Whitney tests were used to assess associations between asthma severity and outcome variables.

Results: Using ERS/ATS 2014 criteria, 31.0% of the patients were identified as SA. SA patients were older at diagnosis (mean age 31.64 years vs 24.71 years, p < 0.001) and had higher proportion of uncontrolled asthma than the NSA patients (64.1% vs 53.2%, p < 0.001). SA patients reported a significantly higher proportion of both hospital admission and emergency room (ER) visits due to asthma in the last year, compared with NSA patients, 8.7% vs. 3.7% (p = 0.011) and 37.0% vs. 21.7% (p < 0.001), respectively.

Conclusions: SA patients were older, had greater proportions in some comorbidities and experienced increased healthcare utilization. Also, our results showed that even in patients using the last steps of treatment (GINA step 4 or 5), there was still a higher proportion of uncontrolled disease.

Citing Articles

Real-World Effectiveness of Mepolizumab in Severe Asthma: Results from the Multi-country, Self-controlled Nucala Effectiveness Study (NEST).

Al-Lehebi R, Al Ahmad M, Maturu V, Mesa A, Mahboub B, Garcia E Adv Ther. 2024; 41(11):4008-4031.

PMID: 39215767 PMC: 11480159. DOI: 10.1007/s12325-024-02967-x.

Overprescription of short-acting β2 agonists: reflections from the SABINA study in Brazil.

Antila M, Souza-Machado A, Gregorio M, Cruz A, Angelini L, Beekman M J Bras Pneumol. 2024; 50(1):e20230174.

PMID: 38422337 PMC: 11095926. DOI: 10.36416/1806-3756/e20230174.

Prevalence of pulmonary hypertension in children with obstructive sleep apnea living at high altitude.

Duenas-Meza E, Severiche-Bueno D, Santos Quintero C, Talani Ochoa J, Ronderos Dummit M, Stapper C Sleep Med X. 2024; 7:100106.

PMID: 38356659 PMC: 10864626. DOI: 10.1016/j.sleepx.2024.100106.

The use of systemic corticosteroids in asthma management in Latin American countries.

Maspero J, Cruz A, Pozo Beltran C, Munive A, Montero-Arias F, Hernandez Pliego R World Allergy Organ J. 2023; 16(4):100760.

PMID: 37179538 PMC: 10172569. DOI: 10.1016/j.waojou.2023.100760.

Breaking the vicious circle-the Asthma Referral Identifier (ReferID) tool.

Beekman M, Hales J, Al-Ahmad M, Del Olmo R, Tan T NPJ Prim Care Respir Med. 2022; 32(1):40.

PMID: 36209272 PMC: 9547879. DOI: 10.1038/s41533-022-00296-6.

References

Bavbek S, Celik G, Ediger D, Mungan D, Sin B, Demirel Y . Severity and associated risk factors in adult asthma patients in Turkey. Ann Allergy Asthma Immunol. 2000; 85(2):134-9. DOI: 10.1016/S1081-1206(10)62453-2. View

Rickham P . HUMAN EXPERIMENTATION. CODE OF ETHICS OF THE WORLD MEDICAL ASSOCIATION. DECLARATION OF HELSINKI. Br Med J. 1964; 2(5402):177. PMC: 1816102. DOI: 10.1136/bmj.2.5402.177. View

Nathan R, Sorkness C, Kosinski M, Schatz M, Li J, Marcus P . Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol. 2004; 113(1):59-65. DOI: 10.1016/j.jaci.2003.09.008. View

Masoli M, Fabian D, Holt S, Beasley R . The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy. 2004; 59(5):469-78. DOI: 10.1111/j.1398-9995.2004.00526.x. View

Antonicelli L, Bucca C, Neri M, De Benedetto F, Sabbatani P, Bonifazi F . Asthma severity and medical resource utilisation. Eur Respir J. 2004; 23(5):723-9. DOI: 10.1183/09031936.04.00004904. View

Neffen H, Fritscher C, Cuevas Schacht F, Levy G, Chiarella P, Soriano J . Asthma control in Latin America: the Asthma Insights and Reality in Latin America (AIRLA) survey. Rev Panam Salud Publica. 2005; 17(3):191-7. DOI: 10.1590/s1020-49892005000300007. View

Braman S . The global burden of asthma. Chest. 2006; 130(1 Suppl):4S-12S. DOI: 10.1378/chest.130.1_suppl.4S. View

Moore W, Bleecker E, Curran-Everett D, Erzurum S, Ameredes B, Bacharier L . Characterization of the severe asthma phenotype by the National Heart, Lung, and Blood Institute's Severe Asthma Research Program. J Allergy Clin Immunol. 2007; 119(2):405-13. PMC: 2837934. DOI: 10.1016/j.jaci.2006.11.639. View

Franco R, Santos A, do Nascimento H, Souza-Machado C, Ponte E, Souza-Machado A . Cost-effectiveness analysis of a state funded programme for control of severe asthma. BMC Public Health. 2007; 7:82. PMC: 1896159. DOI: 10.1186/1471-2458-7-82. View

10.

Ronmark E, Lindberg A, Watson L, Lundback B . Outcome and severity of adult onset asthma--report from the obstructive lung disease in northern Sweden studies (OLIN). Respir Med. 2007; 101(11):2370-7. DOI: 10.1016/j.rmed.2007.06.011. View

11.

de Onis M, Onyango A, Borghi E, Siyam A, Nishida C, Siekmann J . Development of a WHO growth reference for school-aged children and adolescents. Bull World Health Organ. 2007; 85(9):660-7. PMC: 2636412. DOI: 10.2471/blt.07.043497. View

12.

Araujo A, Ferraz E, Borges M, Terra Filho J, Vianna E . Investigation of factors associated with difficult-to-control asthma. J Bras Pneumol. 2007; 33(5):495-501. DOI: 10.1590/s1806-37132007000500003. View

13.

Gamble C, Talbott E, Youk A, Holguin F, Pitt B, Silveira L . Racial differences in biologic predictors of severe asthma: Data from the Severe Asthma Research Program. J Allergy Clin Immunol. 2010; 126(6):1149-56.e1. PMC: 3021754. DOI: 10.1016/j.jaci.2010.08.049. View

14.

Carvalho-Pinto R, Cukier A, Angelini L, Antonangelo L, Mauad T, Dolhnikoff M . Clinical characteristics and possible phenotypes of an adult severe asthma population. Respir Med. 2011; 106(1):47-56. DOI: 10.1016/j.rmed.2011.08.013. View

15.

To T, Stanojevic S, Moores G, Gershon A, Bateman E, Cruz A . Global asthma prevalence in adults: findings from the cross-sectional world health survey. BMC Public Health. 2012; 12:204. PMC: 3353191. DOI: 10.1186/1471-2458-12-204. View

16.

Chung K, Wenzel S, Brozek J, Bush A, Castro M, Sterk P . International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2013; 43(2):343-73. DOI: 10.1183/09031936.00202013. View

17.

Sullivan P, Campbell J, Ghushchyan V, Globe G, Lange J, Woolley J . Characterizing the severe asthma population in the United States: claims-based analysis of three treatment cohorts in the year prior to treatment escalation. J Asthma. 2015; 52(7):669-80. DOI: 10.3109/02770903.2015.1004683. View

18.

Shaw D, Sousa A, Fowler S, Fleming L, Roberts G, Corfield J . Clinical and inflammatory characteristics of the European U-BIOPRED adult severe asthma cohort. Eur Respir J. 2015; 46(5):1308-21. DOI: 10.1183/13993003.00779-2015. View

19.

Deng Q, Lu C, Norback D, Bornehag C, Zhang Y, Liu W . Early life exposure to ambient air pollution and childhood asthma in China. Environ Res. 2015; 143(Pt A):83-92. DOI: 10.1016/j.envres.2015.09.032. View

20.

Sweeney J, Patterson C, Menzies-Gow A, Niven R, Mansur A, Bucknall C . Comorbidity in severe asthma requiring systemic corticosteroid therapy: cross-sectional data from the Optimum Patient Care Research Database and the British Thoracic Difficult Asthma Registry. Thorax. 2016; 71(4):339-46. DOI: 10.1136/thoraxjnl-2015-207630. View